Vaxart, Inc. Vaxart, Inc.

Vaxart, Inc.

VXRT

Rank in Stocks #20203
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Share Price
$0.3661
Last synced: 2026-11-09
Market Cap
$88.90M
Change (1 day)
-1.05%
Change (1 year)
1.69%
Country

Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this

Category

Healthcare
Dividend history for Vaxart, Inc. (VXRT)
Vaxart, Inc. (stock symbol: VXRT) made a total of 1 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $12.19
Dividend yield (TTM) : 0.00%
Dividend payments for Vaxart, Inc. (VXRT) from 2012 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
2026 (TTM) $12.19 0.00%
2012 $12.19 0.00%
List of all dividend payments
Year Dividend Change
2026 (TTM) $1.11 0.00%
2012 $1.11 0.00%
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
0.00%
US
0.00%
US
67.00%
AU
30.00%
BE
0.00%
NL